Neuren Pharmaceuticals (ASX:NEU) Receives FDA Fast Track for NNZ-2591 in Pitt Hopkins Syndrome
Neuren Pharmaceuticals (ASX:NEU) gains FDA Fast Track designation for NNZ-2591 to treat Pitt Hopkins syndrome, following successful Phase 2 trial.
Neuren Pharmaceuticals (ASX:NEU) gains FDA Fast Track designation for NNZ-2591 to treat Pitt Hopkins syndrome, following successful Phase 2 trial.
IDT Australia Limited (ASX:IDT) reports an 83% revenue increase and a 15.8% reduction in loss for the half-year ended December 2024.
Optiscan Imaging Ltd (ASX:OIL) launches InForm™, a groundbreaking pathology imaging device enhancing diagnostic workflows and accuracy.
Pharmx Technologies Limited (ASX:PHX) reports a 17% revenue increase in H1 FY25, driven by strategic growth and partnerships.
Nyrada Inc. (ASX:NYR) reports a 64% revenue decline and a $2.46m loss for the half-year, while advancing its leading drug candidate to clinical trials.
Zelira Therapeutics (ASX:ZLD) secures a $1.15M refund under the R&D Tax Incentive Scheme to advance clinical programs and business operations.
Opthea (ASX:OPT) completes final patient visit in COAST Phase 3 trial, anticipating topline results in early Q2 CY25.
Biome Australia (ASX:BIO) reports its first net profit in H1 FY25 and launches Vision 27 strategic plan with $75-$85m revenue guidance.
Biome Australia Limited (ASX:BIO) reports a 47% revenue increase and a net profit of $433k for the half-year ended 31 December 2024.
Althea Group Holdings (ASX:AGH) raises $4.0 million to expand THC beverage production in North America.